CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Empagliflozin (EMPA), a selective SGLT2 inhibitor, as add-on to basal insulin for 78 weeks improves Glycemic control with weight loss in insulin-treated Type 2 Diabetes (T2DM)
DOI 10.1055/s-0034-1374994
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Rosenstock, A Jelaska, G Kim, UC Broedl, HJ Woerle
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background, methods: We assessed EMPA as add-on to basal insulin in patients with T2DM (n = 494; mean HbA1c 8.2%; BMI 32.2 kg/m2) randomized to double-blind EMPA 10 mg or 25 mg or placebo (PBO) qd for 78 weeks. Basal insulin dose remained constant for the first 18 weeks, then adjusted to meet glucose targets. Primary endpoint was change from baseline in HbA1c at week 18. Key secondary endpoints were changes from bas…
Zitieren
Zitierempfehlung
J Rosenstock, A Jelaska, G Kim, UC Broedl, HJ Woerle (2014) Empagliflozin (EMPA), a selective SGLT2 inhibitor, as add-on to basal insulin for 78 weeks improves Glycemic control with weight loss in insulin-treated Type 2 Diabetes (T2DM). Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1374994
Mit CareLit weiterarbeiten